Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.35 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29030544 | 0.95 | ALDH1A1 (0.33) | ALDH1A1TACR2HPGDKDM4ETDP1 | |
| SCHEMBL25858440 | 0.88 | ALDH1A1 (0.35) | ALDH1A1TACR2KDM4EFDPS | |
| SCHEMBL25858451 | 0.86 | ALDH1A1 (0.34) | ALDH1A1KDM4EMAPTFDPS | |
| SCHEMBL25862575 | 0.80 | TACR2 (0.38) | ALDH1A1TACR2HPGDKDM4ETDP1 | |
| SCHEMBL25260757 | 0.80 | ALDH1A1 (0.37) | ALDH1A1TACR2HPGDKDM4ETDP1 | |
| SCHEMBL31197268 | 0.80 | EHMT2 (0.35) | — | |
| SCHEMBL25859857 | 0.80 | ALDH1A1 (0.35) | ALDH1A1TACR2KDM4EFDPS | |
| SCHEMBL31314127 | 0.80 | ALDH1A1 (0.35) | ALDH1A1TACR2KDM4EFDPS | |
| SCHEMBL31496006 | 0.79 | DHFR (0.35) | ALDH1A1TACR2HPGDKDM4ETDP1 | |
| SCHEMBL25858043 | 0.79 | DHFR (0.35) | ALDH1A1TACR2HPGDKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152584-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-05-15 | — | — | US | disclosed |
| EP-4461729-A1 | ANTIGEN BINDING PROTEIN TARGETING MSLN AND USE THEREOF | Transthera Sciences (Nanjing), Inc. (CN) | 2024-11-13 | — | — | EP | disclosed |
| WO-2023131277-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | 药捷安康(南京)科技股份有限公司 | 2023-07-13 | — | — | WO | disclosed |
| WO-2023131277-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | 药捷安康(南京)科技股份有限公司 | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152584-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USES THEREOF | NLRP3, NLRP1, PYCARD | ALDH1A1 3156/4885TACR2 4031/4885HPGD 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.